title: Adding MUFA to a dietary portfolio of cholesterol-lowering foods reduces apoAI fractional catabolic rate in subjects with dyslipidaemia.
abstract: The present randomised parallel study assessed the impact of adding MUFA to a dietary portfolio of cholesterol-lowering foods on the intravascular kinetics of apoAI- and apoB-containing lipoproteins in subjects with dyslipidaemia. A sample of sixteen men and postmenopausal women consumed a run-in stabilisation diet for 4 weeks. Subjects were then randomly assigned to an experimental dietary portfolio either high or low in MUFA for another 4 weeks. MUFA substituted 13·0% of total energy from carbohydrate (CHO) in the high-MUFA dietary portfolio. Lipoprotein kinetics were assessed after the run-in and portfolio diets using a primed, constant infusion of [2H3]leucine and multicompartmental modelling. The high-MUFA dietary portfolio resulted in higher apoAI pool size (PS) compared with the low-MUFA dietary portfolio (15·9% between-diet difference, P¼0·03). This difference appeared to be mainly attributable to a reduction in apoAI fractional catabolic rate (FCR) after the high-MUFA diet (25·6%, P¼0·02 v. pre-diet values), with no significant change in production rate. The high-MUFA dietary portfolio tended to reduce LDL apoB100 PS compared with the low-MUFA dietary portfolio (228·5% between-diet that adding MUFA to a dietary portfolio of cholesterol-lowering foods provides the added advantage of raising HDL primarily through a reduction in HDL clearance rate. Replacing CHO with MUFA in a dietary portfolio may also lead to reductions in LDL apoB100 concentrations primarily by increasing LDL clearance rate, thus potentiating further the well-known cholesterol-lowering effect of this diet.
authors: Institute of Nutraceuticals and Functional Foods, Laval University, 2440, Boulevard Hochelaga, Québec, QC, Canada G1V 0A6.
authors: Marie-Ève
authors: MÈ
authors: Labonté
authors: David J A
authors: DJ
authors: Jenkins
authors: Gary F
authors: GF
authors: Lewis
authors: Laura
authors: L
authors: Chiavaroli
authors: Julia M W
authors: JM
authors: Wong
authors: Cyril W C
authors: CW
authors: Kendall
authors: Jean-Charles
authors: JC
authors: Hogue
authors: Patrick
authors: P
authors: Couture
authors: Benoît
authors: B
authors: Lamarche
mesh_terms: D000328:Adult; D000924:Anticholesteremic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D016632:Apolipoprotein A-I / Q000097:blood*; D053299:Apolipoprotein B-100 / Q000097:blood*; D002784:Cholesterol / Q000097:blood*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004040:Dietary Carbohydrates / Q000494:pharmacology; D004041:Dietary Fats / Q000097:blood / Q000494:pharmacology*; D050171:Dyslipidemias / Q000097:blood / Q000178:diet therapy*; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017698:Postmenopause
chemical_list: D000924:Anticholesteremic Agents; D016632:Apolipoprotein A-I; D053299:Apolipoprotein B-100; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D004040:Dietary Carbohydrates; D004041:Dietary Fats; D005229:Fatty Acids, Monounsaturated; D002784:Cholesterol